Press Releases

04.29.2025

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

04.26.2025

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

04.24.2025

Pfizer Announces 2025 Shareholder Meeting Preliminary Results

04.23.2025

Pfizer Declares Second-Quarter 2025 Dividend

04.23.2025

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

04.16.2025

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

04.14.2025

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

04.10.2025

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

04.01.2025

European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

03.18.2025

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

03.11.2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

02.24.2025

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference